Ascelia Pharma AB Company Description

Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden.

It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer.

The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden.

Ascelia Pharma AB (publ)

Country	Sweden
Founded	1999
Industry	Biotechnology
Sector	Healthcare
Employees	11
CEO	Magnus Corfitzen

Contact Details

Address: Hyllie Boulevard 34 Malmö, 215 32 Sweden
Phone	46 7 35 17 91 18
Website	ascelia.com

Stock Details

Ticker Symbol	ACE
Exchange	Nasdaq Stockholm
Fiscal Year	January - December
Reporting Currency	SEK
ISIN Number	SE0010573113
SIC Code	2836

Key Executives

Name	Position
Julie Waras Brogren	Deputy Chief Executive Officer and Chief Commercial Officer
Magnus O. Corfitzen	Chief Executive Officer
Andreas Norlin	Chief Scientific Officer
Mikael Widell	Head of IR and Communications